Global Finance News
03 Apr 2026, 10:36
Johnson & Johnson announced that its bladder cancer therapy INLEXZO (gemcitabine intravesical system) has been assigned a permanent billing code in the United States, supporting broader patient access.
The Centers for Medicare & Medicaid Services granted the HCPCS J-code (J9183), effective April 1, enabling standardized reimbursement processes for eligible patients with certain types of non-muscle invasive bladder cancer. The update is expected to simplify administrative procedures for healthcare providers and improve treatment accessibility.
INLEXZO, approved by the FDA in 2025, is the first intravesical drug-releasing system designed to deliver cancer medication directly into the bladder over time, offering an alternative for patients with limited treatment options.
The company said the permanent coding designation represents a key step in reducing access barriers and facilitating more consistent use of the therapy in clinical practice.
The Centers for Medicare & Medicaid Services granted the HCPCS J-code (J9183), effective April 1, enabling standardized reimbursement processes for eligible patients with certain types of non-muscle invasive bladder cancer. The update is expected to simplify administrative procedures for healthcare providers and improve treatment accessibility.
INLEXZO, approved by the FDA in 2025, is the first intravesical drug-releasing system designed to deliver cancer medication directly into the bladder over time, offering an alternative for patients with limited treatment options.
The company said the permanent coding designation represents a key step in reducing access barriers and facilitating more consistent use of the therapy in clinical practice.